These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21235464)

  • 1. Pharmacodynamic biomarkers in model-based drug development in oncology.
    Keizer RJ; Schellens JH; Beijnen JH; Huitema AD
    Curr Clin Pharmacol; 2011 Feb; 6(1):30-40. PubMed ID: 21235464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
    Block M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of analytic methods for biomarkers used in drug development.
    Chau CH; Rixe O; McLeod H; Figg WD
    Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted agents: how to select the winners in preclinical and early clinical studies?
    Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
    Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdialysis: an in vivo approach for measuring drug delivery in oncology.
    Brunner M; Müller M
    Eur J Clin Pharmacol; 2002 Jul; 58(4):227-34. PubMed ID: 12136367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic guided trial design in oncology.
    van Kesteren Ch; Mathôt RA; Beijnen JH; Schellens JH
    Invest New Drugs; 2003 May; 21(2):225-41. PubMed ID: 12889741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of biomarker usage on oncology drug development.
    Hayashi K; Masuda S; Kimura H
    J Clin Pharm Ther; 2013 Feb; 38(1):62-7. PubMed ID: 23057528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current mathematical models for cancer drug discovery.
    Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I
    Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concepts and challenges in quantitative pharmacology and model-based drug development.
    Zhang L; Pfister M; Meibohm B
    AAPS J; 2008 Dec; 10(4):552-9. PubMed ID: 19003542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.
    Bender BC; Schindler E; Friberg LE
    Br J Clin Pharmacol; 2015 Jan; 79(1):56-71. PubMed ID: 24134068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
    Garralda E; Dienstmann R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in cancer - SMi's Seventh Annual Conference.
    Fakorede A
    IDrugs; 2008 Sep; 11(9):627-9. PubMed ID: 18763208
    [No Abstract]   [Full Text] [Related]  

  • 20. Biomarkers in Clinical Trials--SMi Conference. 23-24 September 2009, London, UK.
    Walker G
    IDrugs; 2009 Nov; 12(11):673-4. PubMed ID: 19844848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.